+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cancer Drug Design and Discovery. Edition No. 2

  • ID: 2685443
  • Book
  • 640 Pages
  • Elsevier Science and Technology
1 of 3

Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.

  • Provides a clinical perspective on the development of new molecularly targeted anticancer agents with the latest and most promising chemotherapeutic approaches
  • Offers a broad view of where the field is going, what tools drug discovery is using to produce new agents and how they are evaluated in the laboratory and clinic
  • Features 6 new chapters devoted to advances in technology and successful anticancer therapies, such as cancer genomics and personalized medicine, DNA-targeted agents, B-Raf inhibitors and more
  • Each chapter includes extensive references to the primary and review literature, as well as to relevant web-based sources

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3

Stephen Neidle

Hilary Calvert

Part I. Basic Principles and methodology

Modern cancer drug discovery: integrating targets, technologies and treatments
Paul Workman and Ian Collins

Pharmacogenomics and personalised medicines in cancer treatment
Wei-Peng Yong, Ross Soo and Federico Innocenti

Structural biology and anticancer drug design
Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti

Part II. Drugs in the laboratory and clinic

Temozolomide: from cytotoxic to molecularly-targeted agent
Malcolm Stevens

Temozolomide: patents and the perils of invention
Malcolm Stevens

A new generation of cell-targeted drugs for cancer treatment
Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly

Inhibition of DNA repair as a therapeutic target
Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis
Adrian L. Harris and Daniele G Generali

The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer
Qingzhong Hu and Rolf W. Hartmann

Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting
Zahid H Siddik

Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents
Ian R Hardcastle

Targeting altered metabolism
emerging cancer therapeutic strategy
Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee

Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway
William A Denny and Gordon W. Rewcastle

Antibody-drug conjugates delivering DNA cytotoxics
John A Hartley

Inhibition of telomerase: promise, progress and potential pitfalls
Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan

Targeting B-RAF: the discovery and development of B-RAF inhibitors
Phillip A Harris

Part III. The reality of cancer drugs in the clinic

Failure Modes in Anticancer Drug Discovery and Development
Richard A. Walgren and Christopher. A. Slapak

Anticancer drug registration and regulation: current challenges and possible solutions
David Taylor, Erling Donnelly and Silvia Chioato

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Neidle, Stephen
Stephen Neidle, DSc, PhD, ARCS, FRSC, Director of Cancer Research UK Biomolecular Structure Group, Director of the Centre for Cancer Medicines, Professor of Chemical Biology, The School of Pharmacy, University College London, UK
Note: Product cover images may vary from those shown